Intraoperative Awareness with Propofol-Oxygen Total Intravenous Anesthesia for Microaryngeal Surgery

JEFFREY S. KELLY, M.D.*, RAYMOND C. ROY, M.D., PH.D.†

Microlaryngeal surgery represents a dynamic clinical challenge for both the otolaryngologist and the anesthesiologist. The need to manage the airway cooperatively has led to the development of innovative anesthetic techniques using jet venturi ventilation and total intravenous (IV) anesthesia (TIVA). Propofol (2,6-diisopropylphenol) is an IV anesthetic with well-described characteristics that make it particularly amenable for use in such cases.2,3,4 Recently, however, we encountered a case of intraoperative awareness during TIVA with jet venturi ventilation for laser laryngoscopy using propofol as the sole anesthetic agent.

CASE REPORT

A 46-yr-old, 72-kg man in otherwise good health presented for outpatient carbon dioxide laser treatment of recurrent vocal cord papillomas. He had no drug allergies, took no medication, used alcohol socially, and had previously undergone many identical procedures using a TIVA (methohexital and succinylcholine infusions)-jet venturi ventilation technique without complications. As was his habit, the patient requested an anesthetic compatible with rapid recovery and early discharge. He also refused preanesthetic medication.

In the operating room, iv access and routine anesthetic monitoring were established. Initial blood pressure was 137/80 mmHg, and heart rate was 82 beats/min. After administration of glycopyrrolate 0.2 mg iv, induction proceeded with 150 mg (2.1 mg · kg⁻¹) propofol and 120 mg succinylcholine followed immediately by a propofol infusion via infusion pump at 200 µg · kg⁻¹ · min⁻¹. Hemodynamics after induction remained stable at preinduction levels. Suspension of the larynx and initiation of oxygen-driven proximal jet venturi ventilation as described by Koufman et al. was accompanied by hyperventilation (200/105 mmHg) and tachycardia (122 beats/min), which quickly returned to baseline after a single 5-mg dose of labetalol iv. Anesthetic maintenance consisted of propofol infusion continued at 200 µg · kg⁻¹ · min⁻¹ combined with neuromuscular paralysis using a succinylcholine infusion and titrated to 0/4 switches by train-of-four stimulation of the ulnar nerve. The remainder of the intraoperative course was uneventful. Case duration was 26 min, during which the patient received a cumulative (induction plus maintenance) propofol dose of 450 mg. Emergence from anesthesia was rapid and smooth without hemodynamic perturbations or respiratory compromise.

Upon entering the postanesthesia care unit, the patient spontaneously exclaimed, "I remember all of this one." He described detailed accounts of intraoperative events, such as the surgeon's request for more neuromuscular paralysis because of vocal cord movement and a later request from the surgeon for a spatula to remove burn tissue from the larynx. The patients denied any intraoperative discomfort, including pain or shortness of breath, and remarked that the experience had been quite interesting because "now I know what you guys do to me every 6 weeks."

Close follow-up over the subsequent 18 months revealed the patient to be doing well. He continues to be meaningfully employed and has no psychological problems or sleep disturbances related to this incident.

DISCUSSION

The abolition of memory for intraoperative events (i.e., amnesia) is an integral and desirable component of propo-
The incidence of awareness under general anesthesia is reported to be less than 1%, although its true incidence may be substantially greater (especially in specific patient populations or with certain anesthetic techniques). Regardless of its incidence, the overriding issue concerning intraoperative recall involves the immediate effects (pain, lack of control, inability to communicate) as well as long-term psychological effects (anxiety, depression, sleep disturbances) associated with this event. Some experts consider awareness under anesthesia to constitute negligence when disabling emotional sequelae ensue.

Propofol (2,6-disopropylphenol) is a novel IV anesthetic with pharmacologic properties that encompass many characteristics of an ideal IV anesthetic agent. Its rapid onset and dissipation of action, near absence of prolonged "hangover" effects, and ability to attenuate the cardiovascular response to laryngoscopy make it a logical candidate for use in TIVA-jet ventilator techniques. Use of opioids and/or nitrous oxide with propofol during TIVA is common and attempts to overcome propofol's lack of significant analgesic properties. One review suggests that absence of amnestic effects also may limit propofol's use as the sole agent in TIVA techniques. More recent preliminary data indicate that propofol does produce dose-dependent amnesia, perhaps through enhancement of γ-aminobutyric acid–mediated inhibition in the brain. Absence of a painful stimulus (spinal anesthesia, word or picture recall in healthy volunteers) or attenuation of the painful stimulus by simultaneously administered opioids, however, makes extrapolation of this evidence to our case difficult.

Reports of patients undergoing TIVA with propofol and jet ventilator ventilation are similarly confounded. DeGrood and colleagues reported no awareness in 30 patients randomized to receive either propofol or etomidate TIVA with jet ventilator ventilation for microlaryngeal surgery. One patient in the propofol group, however, did complain of bad dreams associated with the intraoperative period. All patients also received intermittent boluses of alfentanil and topical anesthesia of the larynx with 4% lidocaine. A similar study of 14 patients by Mayné and associates reported no side effects, but their study design did not specifically attempt to elicit recall postoperatively. Best and Traugott reported a randomized single-blind crossover trial comparing propofol with methohexital in 20 patients receiving TIVA-jet ventilator ventilation for recurrent microlaryngeal procedures. All patients received preanesthetic medication in addition to topical anesthesia of the larynx. Their results did not address the issue of intraoperative awareness, although one patient was disturbed by memory of recovery room events after receiving propofol. Harries et al. randomized 40 unpremedicated patients undergoing extracorporeal shock-wave lithotripsy using TIVA-jet ventilator ventilation to receive either propofol or methohexital. All patients also received intermittent bolus fentanyl, topical laryngeal anesthesia, and 50% nitrous oxide. When directly questioned postoperatively, only one patient receiving methohexital TIVA had any intraoperative awareness.

We reviewed anesthetic records from our patient's 17 microlaryngeal procedures to determine factors preventing recall during the other 16 anesthetics (Table 1). Methohexital TIVA (used in 13 of these cases) was associated with concurrent midazolam administration as well as the use of fentanyl in all but one case. Lack of awareness during these methohexital anesthetics is thus not surprising. Despite extensive use of these adjunctive agents, antihypertensive therapy (nitroglycerin and/or β blockers) was required in every case using methohexital TIVA. In the 3 remaining cases of propofol TIVA, the range of induction doses and infusion rates were 160–200 mg and 35–200 μg·kg⁻¹·min⁻¹, respectively. Midazolam and/or fentanyl were administered in all three instances. Treatment for intraoperative hypertension was not required when fentanyl (with or without midazolam) was added to the propofol TIVA technique.

Our case was unique in that the patient received only propofol TIVA and jet ventilator ventilation for his microlaryngeal procedure. No preanesthetic medication or adjunctive anesthetic agents were administered, in contrast to the patient's other anesthetic experiences and the cited propofol TIVA–jet ventilator ventilation studies. It is possible that recall might not have occurred had we used the higher propofol induction dose (2.5 mg·kg⁻¹) shown to...

**Table 1. Summary of Our Patient's 17 Anesthetics**

<table>
<thead>
<tr>
<th>Adjunctive Anesthetic Agents</th>
<th>Total Anesthetics (17)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adjunctive Anesthetic Agents</strong></td>
<td><strong>Menohexial TIVA</strong></td>
</tr>
<tr>
<td>Fentanyl without midazolam</td>
<td>0</td>
</tr>
<tr>
<td>Midazolam without fentanyl</td>
<td>1</td>
</tr>
<tr>
<td>Fentanyl and midazolam</td>
<td>12</td>
</tr>
<tr>
<td>Droperidol</td>
<td>8</td>
</tr>
<tr>
<td>Lidocaine (iv, LTA)</td>
<td>5</td>
</tr>
<tr>
<td>Inhalation agent Pre/Post-JVV</td>
<td>4</td>
</tr>
<tr>
<td>Primary TIVA agent alone</td>
<td>0</td>
</tr>
<tr>
<td>Antihypertensive agents</td>
<td>13</td>
</tr>
</tbody>
</table>

*Intraoperative awareness.

TIVA = total intravenous anesthesia; iv = intravenous; LTA = laryngotracheal administration; JVV = jet ventilator ventilation.
be effective in 95% of unpremedicated patients. This was somewhat mitigated, however, by our use of a constant-rate continuous propofol infusion, as opposed to the progressively decremental propofol infusion rates reported in other TIVA–jet ventilator ventilation series.\textsuperscript{1,7,18,20}

Our patient's hypertension and tachycardia associated with laryngeal suspension could have suggested inadequate anesthetic depth. Autonomic signs, however, are unreliable indicators of awareness secondary to light anesthesia.\textsuperscript{4–6} We chose to treat this episode with labetalol rather than more propofol in view of the patient's wishes for rapid recovery and early discharge.

In summary, we report a case of intraoperative recall during propofol TIVA and jet ventilator ventilation for microlaryngeal surgery. Based on our experience, we have altered our technique to include a larger propofol induction dose combined with midazolam 30–40 \(\mu g\cdot kg^{-1}\) iv and/or fentanyl 1–2 \(\mu g\cdot kg^{-1}\) iv to deepen the level of anesthesia, provide analgesia, and take advantage of the known amnestic properties of benzodiazepines.\textsuperscript{3}

The authors thank Faith McLellan for editorial assistance and Addie Larimore for word processing expertise.

REFERENCES

12. Siler JN, Fisher SM, Boon P: Propofol (P) for total intravenous anaesthesia (TIVA) without nitrous oxide or narcotic infusion (abstract). \textsc{Anesth Analg} 72:5255, 1991
15. Hales TG, Lambert JJ: Modulation of the GABA\(_A\) receptor by propofol: Protein or lipid interaction? (abstract). \textsc{Anesthesiology} 75(suppl):A587, 1991
18. Mayne A, Joucken K, Collard E, Randour P: Intravenous infusion of propofol for induction and maintenance of anaesthesia during endoscopic carbon dioxide laser ENT procedures with high frequency jet ventilation. \textsc{Anaesthesia} 43(suppl):97–100, 1988
19. Best N, Traugott F: Comparative evaluation of propofol or methohexitone as the sole anaesthetic agent for microlaryngeal surgery. \textsc{Anaesthesia Intens Care} 19:50–56, 1991